Innate Pharma's Nectin-4 ADC: A Promising Cancer Treatment on the Horizon

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) has announced an upcoming investor and analyst event focused on its Antibody-Drug Conjugate (ADC) strategy, particularly highlighting IPH4502, its lead Nectin-4 ADC program. The event will take place in New York on February 5, 2025, from 10:00 a.m. to 12:00 p.m. EDT, and will be accessible both in-person and via webcast.

IPH4502 is a novel and differentiated topoisomerase I inhibitor ADC designed to precisely target Nectin-4, a cell adhesion molecule overexpressed in several types of solid tumors, including urothelial carcinoma, breast cancer, non-small cell lung cancer, and gastrointestinal cancer. In non-clinical models, IPH4502 has shown anti-tumor activity in vitro and in vivo, and it has a favorable safety profile in relevant animal toxicology models.

The event will provide an opportunity for investors and analysts to learn about the latest scientific and clinical advancements related to Nectin-4 and its potential in cancer treatment. Key topics to be discussed include:

1. Preclinical data for IPH4502: Innate Pharma will present data from preclinical studies demonstrating the anti-tumor efficacy and safety profile of IPH4502 in various solid tumor models.
2. IND clearance for IPH4502: The company will discuss the recent clearance of its investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 clinical study of IPH4502, marking a significant milestone in the drug's development.
3. IPH45's preclinical data presentation at AACR: Innate Pharma will share details about the oral presentation of IPH45's preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2024, highlighting the potential of IPH45 as a novel and differentiated Nectin-4 ADC with preclinical efficacy in various solid tumor models.
4. Nectin-4's role in cancer: The company will discuss the significance of Nectin-4 as a cell membrane adhesion protein overexpressed in several solid tumors, making it an attractive target for cancer treatment.